Det er også noen avsnitt som, dersom man ønsker å se det på den måten, kan tolkes i retning av en mindre fotosensiterende effekt av pasientens hud.
Men jeg finner ikke noen mer omtale om akkurat det, annet enn at det er en generell utfordring ved PCI. Kan være at jeg tolker det slik jeg har lyst til å tolke det.

"One of the common problems associated with PDT in clinical application is skin photosensitivity and unfavorable biodistribution of photosensitizer. Nanocarriers such as dendrimers, liposomes and polymeric micelles have been introduced as an approach to reduce side effects and to improve pharmacokinetics in PDT.

There remains a need for improved nanocarriers and photosensitizing agents for use in PCI and PDT methods. The present invention addresses this need. The present inventors have developed novel compounds, which are based on a conjugate of a photosensitiser and chitosan. The novel molecules have surprisingly high efficacy in PCI methods, as illustrated in the Examples below which demonstrate surprisingly good efficacy both in vitro and in vivo."